ANALYSIS OF NON-INVASIVE LIVER BIOMARKERS IN A PHASE I I TRIAL OF THE GLUCAGON AND GLP-1 RECEPTOR DUAL AGONIST SURVODUTIDE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) AND FIBROSIS

被引：0

作者：

Noureddin, Mazen ^{[1
]}

Schoelch, Corinna ^{[2
]}

Bugianesi, Elisabetta ^{[3
]}

Alkhouri, Naim ^{[4
,5
]}

Fraessdorf, Mandy ^{[6
]}

Schattenberg, Joern ^{[7
]}

Newsome, Philip ^{[8
]}

Anstee, Quentin ^{[9
]}

Neff, Guy ^{[10
]}

Coxson, Harvey ^{[2
]}

Lawitz, Eric ^{[4
]}

Ratziu, Vlad ^{[11
]}

Nakajima, Atsushi ^{[12
]}

Hosseini-Tabatabaei, Azadeh ^{[13
]}

Sanyal, Arun ^{[14
]}

Younes, Ramy ^{[6
]}

机构：

[1] Houston Methodist Hosp, Houston, TX 77030 USA

[2] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[3] Univ Turin, Div Gastroenterol, Dept Med Sci, Turin, Italy

[4] Univ Texas Hlth San Antonio, Texas Liver Inst, San Antonio, TX USA

[5] Arizona Liver Hlth, Phoenix, AZ USA

[6] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[7] Saarland Univ, Dept Internal Med 2, Med Ctr, Homburg, Germany

[8] Univ Hosp Birmingham, Natl Inst Hlth Res, Biomed Res Ctr, Birmingham, W Midlands, England

[9] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England

[10] Covenant Metab Specialists LLC, Sarasota, FL USA

[11] Sorbonne Univ, Inst Cardiometab & Nutr, Hop Pitie Salpetriere, Paris, France

[12] Yokohama City Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Yokohama, Kanagawa, Japan

[13] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[14] Virginia Commonwealth Univ, Richmond, VA 23284 USA

来源：

HEPATOLOGY | 2024年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

2647

引用

页码：S2005 / S2006

页数：2

共 34 条

[1] Glucagon and GLP-1 receptor dual agonist survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-controlled phase 2 trial
Sanyal, Arun J.
Bedossa, Pierre
Fraessdorf, Mandy
Neff, Guy
Lawitz, Eric
Bugianesi, Elisabetta
Anstee, Quentin M.
Hussain, Samina Ajaz
Newsome, Philip N.
Ratziu, Vlad
Hosseini-Tabatabaei, Azadeh
Schattenberg, Joern M.
Noureddin, Mazen
Alkhouri, Naim
Younes, Ramy
JOURNAL OF HEPATOLOGY, 2024, 80 : S4 - S5
[2] Non-invasive assessment of liver inflammation in metabolic dysfunction-associated steatohepatitis (MASH) using MRI cytometry
Jiang, Xiaoyu
Izzy, Manhal
Washington, Kay
Gore, John
Xu, Junzhong
JOURNAL OF HEPATOLOGY, 2024, 80 : S595 - S595
[3] EFFECT OF PEMVIDUTIDE, A GLP-1/GLUCAGON DUAL RECEPTOR AGONIST, ON PLASMA LIPIDOMIC PROFILES IN SUBJECTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Suschak, John
Andrade, Maynara Lucca
Georges, Bertrand
Browne, Sarah
Alonso, Christina
Harris, Scott
Roberts, Scot
HEPATOLOGY, 2024, 80 : S461 - S462
[4] Effects of Orforglipron, a novel oral GLP-1 receptor agonist, on metabolic dysfunction-associated steatotic liver disease related biomarkers
Sanyal, A.
Loomba, R.
Lin, Y.
Duffin, K.
Wilson, J. M.
Banerjee, H.
Mather, K. J.
Kazda, C.
Konig, M.
DIABETOLOGIA, 2024, 67 : S354 - S355
[5] Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist
Roux, Carel W. Ie
Steen, Oren
Lucas, Kathryn J.
Startseva, Elena
Unseld, Anna
Hussain, Samina Ajaz
Hennige, Anita M.
DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1773 - 1782
[6] COST-COMPARISON ANALYSIS OF NON-INVASIVE TESTING STRATEGIES FOR METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) IN VETERAN POPULATION
Boltyenkov, A.
Chang, S.
Chalfin, D. B.
Sangha, K.
Cheung, R.
VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
[7] Non-invasive biomarkers of liver fibrosis may be used for diagnosing fibrosis and prognostication in patients with metabolic dysfunction-associated steatotic liver disease
Hetland, Liv Eline
Werge, Mikkel
Thing, Mira
Rashu, Elias
Nabilou, Puria
Kimer, Nina
Junker, Anders
Leeming, Diana
Karsdal, Morten
Guiliani, Alejandro Mayorca
Gluud, Lise Lotte
JOURNAL OF HEPATOLOGY, 2024, 80 : S513 - S513
[8] SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
Alkhouri, Naim
Fraessdorf, Mandy
Neff, Guy
Schattenberg, Joern M.
Noureddin, Mazen
Lawitz, Eric
Anstee, Quentin M.
Bugianesi, Elisabetta
Hussain, Samina Ajaz
Newsome, Philip
Ratziu, Vlad
Hosseini-Tabatabaei, Azadeh
Sanyal, Arun J.
Younes, Ramy
GASTROENTEROLOGY, 2024, 166 (05)
[9] Survodutide, a glucagon receptor/GLP-1 receptor (GCGR/GLP-1R) dual agonist, improves cardiometabolic parameters in adults with obesity: analysis of a placebo-controlled, randomised phase 2 trial
Le Roux, C.
Steen, O.
Lucas, K. J.
Ekinci, E., I
Startseva, E.
Unseld, A.
Hennige, A. M.
EUROPEAN HEART JOURNAL, 2024, 45
[10] Pemvidutide, a glucagon-like peptide 1/glucagon dual receptor agonist, improves metabolic dysfunction-associated steatohepatitis activity and fibrosis in a clinical quantitative systems pharmacology model
Harrison, Stephen A.
Suschak, John
McDaniel, Matthew
Kenz, Zackary
Tomah, Shaheen
Kasper, Jonathan
Roberts, M. Scot
Siler, Scott
Harris, M. Scott
Browne, Sarah
JOURNAL OF HEPATOLOGY, 2024, 80 : S517 - S517

← 1 2 3 4 →